A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. This document reports that recombinant human Interferon-B 1a potently inhibits SARS coronavirus replication in vitro.
Center for Disease Control and Prevention: www.cdc.gov
Emerging Infectious Diseases (February 2004), v.10, no.2, p. 317-319